Prostate-specific antigen. Improving its ability to diagnose early prostate cancer

Editorial

J E Oesterling. JAMA. 1992 Apr.

. 1992 Apr;267(16):2236-8.

doi: 10.1001/jama.267.16.2236.

No abstract available

Comment in

Cancer of the prostate.
Carlson SE. Carlson SE. JAMA. 1992 Dec 9;268(22):3196; author reply 3199. doi: 10.1001/jama.268.22.3196b. JAMA. 1992. PMID: 1279228 No abstract available.
Cancer of the prostate.
Goodwin P, Wall E. Goodwin P, et al. JAMA. 1992 Dec 9;268(22):3196; author reply 3199. doi: 10.1001/jama.1992.03490220040012. JAMA. 1992. PMID: 1279229 No abstract available.
Cancer of the prostate.
Stuart ME, Handley MR, Conger MR. Stuart ME, et al. JAMA. 1992 Dec 9;268(22):3197-8; author reply 3199. JAMA. 1992. PMID: 1279231 No abstract available.
Cancer of the prostate.
Layson RT. Layson RT. JAMA. 1992 Dec 9;268(22):3197; author reply 3199. doi: 10.1001/jama.1992.03490220040013. JAMA. 1992. PMID: 1433753 No abstract available.
Cancer of the prostate.
Wilt TJ, Joseph AM, Enstud KE. Wilt TJ, et al. JAMA. 1992 Dec 9;268(22):3198-9. doi: 10.1001/jama.1992.03490220040017. JAMA. 1992. PMID: 1433755 No abstract available.

Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease.
Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, Fozard JL, Walsh PC. Carter HB, et al. JAMA. 1992 Apr 22-29;267(16):2215-20. JAMA. 1992. PMID: 1372942 Free PMC article.
The effect of digital rectal examination on prostate-specific antigen levels.
Crawford ED, Schutz MJ, Clejan S, Drago J, Resnick MI, Chodak GW, Gomella LG, Austenfeld M, Stone NN, Miles BJ, et al. Crawford ED, et al. JAMA. 1992 Apr 22-29;267(16):2227-8. JAMA. 1992. PMID: 1372943 Clinical Trial.
High 10-year survival rate in patients with early, untreated prostatic cancer.
Johansson JE, Adami HO, Andersson SO, Bergström R, Holmberg L, Krusemo UB. Johansson JE, et al. JAMA. 1992 Apr 22-29;267(16):2191-6. JAMA. 1992. PMID: 1556796

Production of milligram concentrations of free prostate specific antigen (fPSA) from LNCaP cell culture: difference between fPSA from LNCaP cell and seminal plasma.
Wu JT, Lyons BW, Liu GH, Wu LL. Wu JT, et al. J Clin Lab Anal. 1998;12(1):6-13. doi: 10.1002/(SICI)1098-2825(1998)12:1<6::AID-JCLA2>3.0.CO;2-A. J Clin Lab Anal. 1998. PMID: 9484663 Free PMC article.
STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors.
Hubert RS, Vivanco I, Chen E, Rastegar S, Leong K, Mitchell SC, Madraswala R, Zhou Y, Kuo J, Raitano AB, Jakobovits A, Saffran DC, Afar DE. Hubert RS, et al. Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14523-8. doi: 10.1073/pnas.96.25.14523. Proc Natl Acad Sci U S A. 1999. PMID: 10588738 Free PMC article.
Prostate-specific antigen testing practices and outcomes.
Hoffman RM, Blume P, Gilliland F. Hoffman RM, et al. J Gen Intern Med. 1998 Feb;13(2):106-10. doi: 10.1046/j.1525-1497.1998.00026.x. J Gen Intern Med. 1998. PMID: 9502370 Free PMC article.
Screening for ovarian, prostatic, and testicular cancers.
Austoker J. Austoker J. BMJ. 1994 Jul 30;309(6950):315-20. doi: 10.1136/bmj.309.6950.315. BMJ. 1994. PMID: 7522074 Free PMC article. Review.
Changes of serum prostate-specific antigen following high energy thick loop prostatectomy.
Talic RF, El-Tiraifi AM, Altaf S, Hargreave TB. Talic RF, et al. Int Urol Nephrol. 2000;32(2):271-4. doi: 10.1023/a:1007170029017. Int Urol Nephrol. 2000. PMID: 11229647